Drug Database
Back to search

Belgium· BE-AMP-SAM582604-00

Ontozry 50 mg

A cenobamate product containing cenobamate, registered in Belgium by Aziende Chimiche Riunite Angelini Francesco. The same ATC class is registered in 15 of our 19 countries.

ATC N03AX25

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOntozry 50 mgATCN03AX25REGISTER NO.BE-AMP-SAM582604-00PACKS LISTED6CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cenobamateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cenobamate is registered in 15 of 19 countries.

Countries holding a registration under ATC N03AX25 (cenobamate), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 10 of them publish a price we can compare per daily dose
Search cenobamate products by name

Cenobamate · ATC N03AX25

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cenobamate costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $4.11 in France to $21.72 in Switzerland — a ×5.3 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cenobamate · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$21.72
  • IT Italy$19.89
  • CZ Czechia$4.12
  • FR France$4.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Cenobamate
Manufacturer
Aziende Chimiche Riunite Angelini Francesco
Country
Belgium (BE)
ATC code
N03AX25
ATC class
Cenobamate
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 6

3 priced
  • be_apb
    4581062
    EUR 118.69
  • be_apb
    4933263
    EUR 118.69
  • be_apb
    5871090
    EUR 118.69
  • be_apb
    7735640
  • be_apb
    7747355
  • be_apb
    7750342

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

273 interactions on record for cenobamate.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cenobamate against other medicinesHow interaction checks work

Cenobamate · interactions on record

273 records

  • 29 severe
  • 237 moderate
  • 7 minor

Most severe, free to view

  • DeflazacortH02AB13severe
  • BosutinibL01EA04severe
  • EncorafenibL01EC03severe
  • BrigatinibL01ED04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cenobamate in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cenobamate products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ontozry
  • Liechtenstein · Ontozry
  • Norway · Ontozry

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e56e7dd1-e4a3-4940-8ee8-ed86c79406b9
GET /v1/drugs/e56e7dd1-e4a3-4940-8ee8-ed86c79406b9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ontozry 50 mg",
  "name_fr": "Ontozry 50 mg",
  "name_nl": "Ontozry 50 mg",
  "amp_code": "SAM582604-00",
  "strengths": [
    "50.0000",
    "50.0000",
    "158.7000"
  ],
  "pack_count": 5,
  "substances": [
    "Cenobamate",
    "Lactose Monohydrate",
    "Sodium Starch Glycolate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Cenobamate",
  "authorisation_numbers": [
    "EU/1/21/1530/002",
    "EU/1/21/1530/003",
    "EU/1/21/1530/004"
  ]
}
API referenceMCP serverPlans

See everything about cenobamate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console